Hypoxia-induced angiogenesis functions importantly in anaplastic thyroid cancer (ATC) progression. However, the therapeutic potential of broad-spectrum anti-angiogenic agent remains undefined. Anlotinib conventionally targets VEGFR, FGFR and PDGFR. Here, a novel role of anlotinib on ATC angiogenesis was illustrated.
Molecular expressions were established via tissue microarray. Multiple assays (tubule formation, 3D sprouting and chicken chorioallantoic membrane model) were used for angiogenic evaluation. Panels of molecular screening were achieved by antibody and PCR arrays. The loop binding motif of EGFR for homology modelling was prepared using Maestro.
Anlotinib could dose- and time-dependently inhibit cell viability under normoxia and hypoxia and could repress hypoxia-activated angiogenesis more efficiently in vitro and in vivo. CXCL11 and phospho-EGFR were hypoxia-upregulated with a positive correlation. The cancer–endothelium crosstalk could be mediated by the positive CXCL11-EGF-EGFR feedback loop, which could be blocked by anlotinib directly targeting EGFR via a dual mechanism by simultaneous inhibitory effects on cancer and endothelial cells. The AKT-mTOR pathway was involved in this regulatory network.
The newly identified CXCL11-EGF-EGFR signalling provided mechanistic insight into the interaction between cancer and endothelial cells under hypoxia, and EGFR was a novel target. Anlotinib may be the encouraging therapeutic candidate in ATC.
Subscribe to Journal
Get full journal access for 1 year
only $16.63 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA: A Cancer J. Clin. 70, 7–30 (2020).
Xu, B. & Ghossein, R. Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma. Endocr. Pathol. 27, 205–212 (2016).
Molinaro, E., Romei, C., Biagini, A., Sabini, E., Agate, L., Mazzeo, S. et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 13, 644–660 (2017).
Wu, H., Sun, Y., Ye, H., Yang, S., Lee, S. L. & de las Morenas, A. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets. Pathol. Oncol. Res. 21, 695–701 (2015).
Saini, S., Tulla, K., Maker, A. V., Burman, K. D. & Prabhakar, B. S. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol. Cancer 17, 154 (2018).
Smallridge, R. C. & Copland, J. A. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin. Oncol. 22, 486–497 (2010).
Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y. & Fujii-Kuriyama, Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl Acad. Sci. USA 94, 4273–4278 (1997).
Niu, Y., Bao, L., Chen, Y., Wang, C., Luo, M., Zhang, B. et al. HIF2-induced long noncoding RNA RAB11B-AS1 promotes hypoxia-mediated angiogenesis and breast cancer metastasis. Cancer Res. 80, 964 (2020).
Hogenesch, J. B., Gu, Y. Z., Jain, S. & Bradfield, C. A. The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. Proc. Natl Acad. Sci. USA 95, 5474–5479 (1998).
Schito, L. & Semenza, G. L. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer 2, 758–770 (2016).
Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
Wang, G. L., Jiang, B. H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 92, 5510–5514 (1995).
Rey, S., Schito, L., Wouters, B. G., Eliasof, S. & Kerbel, R. S. Targeting hypoxia-inducible factors for antiangiogenic cancer therapy. Trends Cancer 3, 529–541 (2017).
Ha, H. T., Lee, J. S., Urba, S., Koenig, R. J., Sisson, J., Giordano, T. et al. A Phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20, 975–980 (2010).
Bueno, M. J., Mouron, S. & Quintela-Fandino, M. Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach. Br. J. Cancer 116, 1119–1125 (2017).
Sun, Y., Niu, W., Du, F., Du, C., Li, S., Wang, J., Li, L., Wang, F. et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J. Hematol. Oncol. 9, 105 (2016).
Cheng, X., Jin, Z., Ji, X., Shen, X., Feng, H., Morgenlander, W. et al. ETS variant 5 promotes colorectal cancer angiogenesis by targeting platelet-derived growth factor BB. Int. J. Cancer 145, 179–191 (2019).
Nowak-Sliwinska, P., Alitalo, K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R. et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis 21, 425–532 (2018).
Fu, Z., Cheng, X., Kuang, J., Feng, H., Chen, L., Liang, J. et al. CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species. Mol. Oncol. 12, 529–544 (2018).
Feng, H., Cheng, X. I., Kuang, J., Chen, L., Yuen, S., Shi, M. et al. Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer. Cell Death Dis. 9, 1030 (2018).
Koo, Y. J., Kim, T. J., Min, K. J., So, K. A., Jung, U. S. & Hong, J. H. CXCL11 mediates TWIST1-induced angiogenesis in epithelial ovarian cancer. Tumour Biol. 39, 1010428317706226 (2017).
Puchert, M., Obst, J., Koch, C., Zieger, K. & Engele, J. CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7. Cytokine 125, 154809 (2020).
Shen, M., Feng, Y., Wang, J., Yuan, Y. & Yuan, F. CXCR7 inhibits fibrosis via Wnt/β-catenin pathways during the process of angiogenesis in human umbilical vein endothelial cells. Biomed. Res. Int. 2020, 1216926 (2020).
Liu, Y., Calmel, C., Desbois‐Mouthon, C., Sobczak‐Thépot, J., Karaiskou, A. & Praz, F. Regulation of the EGFR/ErbB signalling by clathrin in response to various ligands in hepatocellular carcinoma cell lines. J. Cell Mol. Med. 24, 8091–8102 (2020).
Ensinger, C., Spizzo, G., Moser, P., Tschoerner, I., Prommegger, R., Gabriel, M. et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann. N. Y. Acad. Sci. 1030, 69–77 (2005).
Huang, L. C., Tam, K. W., Liu, W. N., Lin, C. Y., Hsu, K. W., Hsieh, W. S. et al. CRISPR/Cas9 genome editing of epidermal growth factor receptor sufficiently abolished oncogenicity in anaplastic thyroid cancer. Dis. Markers 2018, 1–14 (2018).
Lopez, J. P., Wang-Rodriguez, J., Chang, C., Chen, J. S., Pardo, F. S., Aguilera, J. et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch. Otolaryngol. Head Neck Surg. 133, 1022–1027 (2007).
Liang, L., Hui, K., Hu, C., Wen, Y., Yang, S., Zhu, P. et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. J. Exp. Clin. Cancer Res. 38, 71 (2019).
Lu, J., Zhong, H., Chu, T., Zhang, X., Li, R., Sun, J. et al. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy. Eur. Respir. J. 53, 1801562 (2019).
Ruan, X., Shi, X., Dong, Q., Yu, Y., Hou, X., Song, X. et al. Antitumor effects of anlotinib in thyroid cancer. Endocr. Relat. Cancer 26, 153–164 (2019).
Majmundar, A. J., Wong, W. J. & Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294–309 (2010).
Semenza, G. L., Nejfelt, M. K., Chi, S. M. & Antonarakis, S. E. Hypoxia-inducible nuclear factors bind to an enhancer element located 3’ to the human erythropoietin gene. Proc. Natl Acad. Sci. USA 88, 5680–5684 (1991).
Singh, A. K., Arya, R. K., Trivedi, A. K., Sanyal, S., Baral, R., Dormond, O. et al. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev. 24, 41 (2013).
Hensbergen, P. J., Wijnands, P. G. B., Schreurs, M. W., Scheper, R. J., Willemze, R. & Tensen, C. P. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J. Immunother. 28, 343–351 (2005).
Wang, P., Yang, X., Xu, W., Li, K., Chu, Y. & Xiong, S. Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy. Cancer Immunol. Immunother. 59, 1715–1726 (2010).
Rupertus, K., Sinistra, J., Scheuer, C., Nickels, R. M., Schilling, M. K., Menger, M. D. et al. Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer. Clin. Exp. Metastasis 31, 447–459 (2014).
Werner, T. A., Forster, C. M., Dizdar, L., Verde, P. E., Raba, K., Schott, M. et al. CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma. Br. J. Cancer 117, 1837–1845 (2017).
Billottet, C., Quemener, C. & Bikfalvi, A. CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochimica et. Biophysica Acta 1836, 287–295 (2013).
Miao, Z., Luker, K. E., Summers, B. C., Berahovich, R., Bhojani, M. S., Rehemtulla, A. et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl Acad. Sci. USA 104, 15735 (2007).
Singh, R. K. & Lokeshwar, B. L. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res. 71, 3268–3277 (2011).
Dai, Y. J., Qiu, Y. B., Jiang, R., Xu, M., Zhao, L., Chen, G. G. et al. Concomitant high expression of ERα36, EGFR and HER2 is associated with aggressive behaviors of papillary thyroid carcinomas. Sci. Rep. 7, 12279 (2017).
Zhao, L., Zhu, X. Y., Jiang, R., Xu, M., Wang, N., Chen, G. G. et al. Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma. Int. J. Clin. Exp. Pathol. 8, 11236–11247 (2015).
Keller, S. & Schmidt, M. H. EGFR and EGFRvIII promote angiogenesis and cell invasion in glioblastoma: combination therapies for an effective treatment. Int. J. Mol. Sci. 18, 1295 (2017).
De Luca, A., Carotenuto, A., Rachiglio, A., Gallo, M., Maiello, M. R., Aldinucci, D. et al. The role of the EGFR signaling in tumor microenvironment. J. Cell. Physiol. 214, 559–567 (2008).
Yu, X., Li, W., Deng, Q., You, S., Liu, H., Peng, S. et al. Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production. Mol. Carcinogenesis 56, 1414–1426 (2017).
Dittmann, K., Mayer, C., Czemmel, S., Huber, S. M. & Rodemann, H. P. New roles for nuclear EGFR in regulating the stability and translation of mRNAs associated with VEGF signaling. PLoS ONE 12, e0189087 (2017).
Lin, B., Song, X., Yang, D., Bai, D., Yao, Y. & Lu, N. A. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene 654, 77–86 (2018).
Han, B., Li, K., Zhao, Y., Li, B., Cheng, Y., Zhou, J. et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br. J. Cancer 118, 654–661 (2018).
Wang, G., Sun, M., Jiang, Y., Zhang, T., Sun, W., Wang, H. et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int. J. Cancer 145, 979–993 (2019).
Tang, L., Yu, W., Wang, Y., Li, H. & Shen, Z. Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. Clin. Transl. Oncol. 21, 1624–1633 (2019).
Ethics approval and consent to participate
Ethics approval was granted by the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Animal experiments were carried out according to the Ruijin Hospital Animal Care and Use Guidelines, and the experimental protocols were approved by the Shanghai Resource Center of Laboratory Animals of the Chinese Academy of Science. The manuscript was in accordance with the reporting ARRIVE guideline, and with the Declaration of Helsinki. Written informed consents were obtained from all patients.
Consent to publish
All data generated or analysed during this study are included in this published article and its supplementary information files.
The authors declare no competing interests.
This work was supported by the Nature Science Foundation of China (NSFC, 81772558, 82072948).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Liang, J., Jin, Z., Kuang, J. et al. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br J Cancer (2021). https://doi.org/10.1038/s41416-021-01340-x